History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies (i.e., antibodies with generic names ending in \ximab\ or \zumab\, respectively) or fusion proteins
No known history of severe allergic anaphylactic reactions to chimeric, human or humanized antibodies, or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
The patient must NOT have a history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins;
MEDICATION-RELATED: History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanised antibodies or fusion proteins
History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins or Chinese hamster ovary cell products.
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
(Atezolizumab-related exclusion) History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
Patients who have a history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins are not eligible
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
Patients who have a history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic or hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other reactions to chimeric or humanized antibodies or fusion proteins.
History of severe (or known) hypersensitivity to chimeric or humanized antibodies or fusion proteins or any component of atezolizumab formulation
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins or eribulin
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
Phase 1b and crossover only: History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins; Known hypersensitivity to Chinese Hamster Ovary (CHO)-cell products; Allergy or hypersensitivity to components of the atezolizumab formulation
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
Known hypersensitivity to any component of the MPDL3280A or rociletinib formulations or history or hypersensitivity to chimeric humanized antibodies or fusion proteins
History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein
History of severe reactions (e.g. allergic, anaphylactic, or other hypersensitivity) to chimeric or humanized antibodies or fusion proteins
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
History of severe hypersensitivity reaction to monoclonal antibodies.
History of severe hypersensitivity reactions to other mAbs
History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)
A history of hypersensitivity to other humanized monoclonal antibodies.
History of severe hypersensitivity reactions to other monoclonal antibodies.
Patient has history of severe hypersensitivity reactions to other monoclonal antibodies (mAbs).
Severe hypersensitivity to other monoclonal antibodies (mAbs).
History of severe hypersensitivity reactions to other monoclonal antibodies
History of severe hypersensitivity reactions (eg, anaphylaxis) to other biologic drugs or monoclonal antibodies
History of severe hypersensitivity reactions to other monoclonal antibodies
History of severe hypersensitivity reactions to monoclonal antibodies.
Hypersensitivity to any of the inactive ingredients (histidine, sucrose, polysorbate 80) or to other humanized monoclonal antibodies (mAbs)
No history of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)
History of grade >= 3 allergy to human monoclonal antibodies
Monoclonal antibodies therapy within 2 weeks before study entry
History of severe allergic reactions to humanized monoclonal antibodies
History of severe hypersensitivity reactions to other monoclonal antibodies
History of severe hypersensitivity reactions to other monoclonal antibodies
Severe hypersensitivity reactions to monoclonal antibodies, known hypersensitivity to the investigational medicinal products or to one or more of the excipients, autoimmune diseases (inflammatory bowel diseases, interstitial lung disease, or pulmonary fibrosis), and live vaccines within 28 days prior to study entry.
History of severe hypersensitivity reactions to other monoclonal antibodies
Known prior hypersensitivity to the investigational product or any component formulations, including known severe hypersensitivity reactions to monoclonal antibodies
History of sensitivity or allergy to monoclonal antibodies (mAbs) or immunoglobulin G (IgG)
No history of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)
Allergy to murine-based monoclonal antibodies
Prior hypersensitivity to monoclonal antibodies
Monoclonal antibodies therapy within 2 weeks before study entry
History of grade 3 or higher allergy to humanized monoclonal antibodies
History of severe allergic reactions to humanized monoclonal antibodies
History of severe hypersensitivity reactions to other monoclonal Antibodies
History of grade 3 or above hypersensitivity reactions to other monoclonal antibodies
Patients with history of hypersensitivity to monoclonal antibodies
History of sensitivity or allergy to monoclonal antibodies or immunoglobulin G
Patients who have experienced allergic reactions to monoclonal antibodies
History of severe hypersensitivity reactions to other mAbs
History of severe hypersensitivity reaction to other monoclonal antibodies
No known hypersensitivity to rat monoclonal antibodies
Monoclonal antibodies therapy within 2 weeks before study entry
No history of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)
History of severe hypersensitivity reactions to other mAbs
History of severe hypersensitivity to monoclonal antibodies (mAbs).
History of severe hypersensitivity reactions to other monoclonal antibodies.
Patients with known hypersensitivity to any of the components of MCLA-117 or who have had prior hypersensitivity reactions to human or humanized monoclonal antibodies;
History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs).
Prior hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins, or immunotherapy.
History of severe hypersensitivity reaction with biologics therapy (monoclonal antibodies)
Known hypersensitivity to monoclonal antibodies
History of severe hypersensitivity reactions to other monoclonal antibodies which in the opinion of the investigator may pose an increased risk of a serious infusion reaction.
History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)
History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)
History of severe hypersensitivity reactions to other monoclonal antibodies.
History of severe hypersensitivity reactions/anaphylaxis attributed to humanized and/or chimeric monoclonal antibodies or other such proteins; hypersensitivity reactions that are clearly related to cetuximab may be permitted at the discretion of the principal investigator
For Combination Dose Finding and Combination Expansion cohorts only: history of hypersensitivity reactions/anaphylaxis attributed to humanized and/or chimeric monoclonal antibodies or other such proteins; hypersensitivity reactions that are clearly related to cetuximab may be permitted at the discretion of the lead principal investigator (PI)
History of allergy to mesothelin-directed antibodies, tubulysin, monoclonal antibodies, nivolumab or related compounds
History of allergy or hypersensitivity to human, humanized or chimeric monoclonal antibodies
History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)
History of severe hypersensitivity reactions to other mAbs.
A history of allergy to human monoclonal antibodies.
History of grade 3 or higher hypersensitivity reactions/anaphylaxis attributed to humanized and/or chimeric monoclonal antibodies or other such proteins; hypersensitivity reactions that are clearly related to cetuximab may be permitted at the discretion of the principal investigator
Subject has a known hypersensitivity to monoclonal antibodies or to agents of similar biologic composition as IMC-CS4.
History of severe hypersensitivity reactions to other biologic drugs or monoclonal antibodies
Known severe hypersensitivity reactions to monoclonal antibodies (Grade ?3), any history of anaphylaxis.
History of severe hypersensitivity reactions to other monoclonal antibodies
Hypersensitivities to other monoclonal antibodies;
Known hypersensitivity to any of the components of MM-302 or who have had hypersensitivity reactions to fully human monoclonal antibodies
Monoclonal antibodies within 28 days
History of severe hypersensitivity reactions or immune related adverse events to other monoclonal antibodies
Prior hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins, or immunotherapy.
Prior hypersensitivity to monoclonal antibodies
History of Grade ? 3 allergy to human monoclonal antibodies.
History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (e.g. monoclonal antibodies, polyclonal gamma globulin, polysorbates)
History of allergic reactions to monoclonal antibodies
History of severe hypersensitivity reactions to other mAbs.
History of severe hypersensitivity to monoclonal antibodies.
History of severe hypersensitivity to monoclonal antibodies or to the chemotherapies under investigation including any ingredient used in the formulation.
History of severe hypersensitivity reactions to other monoclonal antibodies.
History of severe hypersensitivity reactions to other monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction.
Known allergy or hypersensitivity to monoclonal antibodies
History of severe hypersensitivity reactions to other monoclonal antibodies.
History of severe hypersensitivity reaction to other monoclonal antibodies
Patients with a history of a serious allergic or anaphylactic reaction to humanized monoclonal antibodies are not eligible
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
History of severe allergic or anaphylactic reaction to humanized or murine monoclonal antibodies
Have a history of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational drug
Intolerance to or prior severe (?Grade 3) allergic or anaphylactic reaction to infused antibodies or infused therapeutic proteins.
History of severe allergic or anaphylactic reaction to humanized or murine monoclonal antibodies (for participants receiving regimen including rituximab).
Patients with a suspected allergy or sensitivity to any component of MT-3724 drug preparation based upon known allergies to compounds of a similar class who have had an anaphylactic or other severe infusion reaction to human immunoglobulin or monoclonal antibody administration are n ot eligible.
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or a known hypersensitivity to bakerâ€™s yeast, unless in consultation with an allergy specialist they are deemed eligible for retreatment with desensitization
History of Grade 4 anaphylactic reaction to monoclonal antibody therapy.
History of severe (defined as grade 4 and/or requiring permanent discontinuation of prior antibody therapy) allergic or anaphylactic reactions to human, humanized, chimeric, or murine monoclonal antibodies
History of anaphylactic reaction to a recombinant protein or hypersensitivity to PEG
History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent
History of severe allergic or anaphylactic reactions to previous monoclonal antibody therapy;
History of anaphylactic reaction to monoclonal antibody therapy
Patients with intolerance to or who have had a severe allergic or anaphylactic reaction to antibodies or infused therapeutic proteins, or patients who have had a severe allergic or anaphylactic reaction to any of the substances included in the study drug (including excipients)
History of anaphylactic reaction to monoclonal antibody therapy
History of severe allergic, anaphylactic, or other hypersensitivity reactions to gemcitabine or nab-paclitaxel
History of anaphylactic reaction to human, or humanized, antibody
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
Patients with intolerance to or who have had a severe (>= grade 3) allergic or anaphylactic reaction to antibodies or infused therapeutic proteins, or patients who have had a severe allergic or anaphylactic reaction to any of the substances included in the investigational product (including excipients)
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (eg, subjects in whom re-administration with rituximab would be contraindicated for safety reasons).
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
History of severe allergic or anaphylactic reactions to human monoclonal antibody therapy or known hypersensitivity to any Probody therapeutic.
History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent
History of anaphylactic reaction to human, or humanized, antibody
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
Severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational product
History of severe allergic or anaphylactic reactions to previous monoclonal antibody therapy;
History of grade IV anaphylactic reaction to monoclonal antibody therapy
History of allergic or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody (IgG protein) or molecules made of components of monoclonal antibodies (e.g., Enbrel which is the Fc portion of an antibody or Lucentis which is a Fab)
Participants with a history of allergic reactions attributed to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent
History of anti-drug antibodies, severe allergic, anaphylactic, or other infusion-related reaction to a previous biologic agent
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
History of severe allergic or anaphylactic reaction or known sensitivity to humanized or murine monoclonal antibodies
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
History of anaphylactic reaction following exposure to humanized or human therapeutic monoclonal antibodies, hypersensitivity to GM-CSF or yeast derived products, clinically meaningful allergic reactions or any known hypersensitivity or prior reaction to any of the formulation excipients in the study drugs.
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
History of solid organ transplantation and of severe allergic or anaphylactic reaction to humanized, chimeric, or murine monoclonal antibodies
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of severe (defined as grade 4 and/or requiring permanent discontinuation of prior antibody therapy) allergic or anaphylactic reactions to human, humanized, chimeric, or murine monoclonal antibodies
History of severe allergic or anaphylactic reactions to monoclonal antibodies
History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or a known hypersensitivity to any of the other study drugs
Previous life-threatening anaphylactic reactions to prior monoclonal antibody-based immunotherapy or any component of the moxetumomab pasudotox formulation
Intolerance to rituximab or severe allergic or anaphylactic reaction to any humanized or murine monoclonal antibodies
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
Severe allergic or anaphylactic reaction to any monoclonal antibody therapy, murine protein, or known hypersensitivity to any of the study drugs
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
Transformation of CLL to aggressive B-cell malignancy History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of severe (e.g. anaphylactic) reactions to blood or to any blood-derived product.
History of severe allergic or anaphylactic reaction or hypersensitivity to recombinant protein
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (MAbs, or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (e.g., patients in whom dosing with obinutuzumab would be contraindicated for safety reasons)
History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
Severe hypersensitivity reaction to apixaban, dalteparin, heparin or pork products (e.g., anaphylactic reactions)
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
History of severe allergic or anaphylactic reaction or hypersensitivity to recombinant proteins or excipients in investigational product
History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies
Severe hypersensitivity reaction to apixaban (e.g., anaphylactic reactions)
History of anaphylactic reactions or severe allergies
Patients with a history of anaphylactic reactions to OTL38
History of anaphylactic reaction to human, or humanized, antibody
Previous anaphylactic reaction to either FDHT or FDG
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or to the chemotherapy drugs used in this study, unless the antibody can be given through a desensitization program in consultation with an allergist
Previous anaphylactic reaction to human, humanized or chimeric antibody
Previous anaphylactic reaction to huJ591 antibody or FDG imaging
Participant has a history of severe allergic or anaphylactic reactions to recombinant proteins or excipients used in TAK-164 formulation.
History of anaphylactic reactions or severe allergies
Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 grade >= 3) that could interfere with study endpoints or put patient safety at risk
Known severe hypersensitivity reactions to monoclonal antibodies; any history of anaphylaxis or uncontrolled asthma.
Known severe (grade >= 3 NCI-CTCAE) hypersensitivity reactions to monoclonal antibodies, or history of anaphylaxis.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin, paclitaxel or avelumab, including known severe hypersensitivity reactions to monoclonal antibodies (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v]5.0 grade >= 3)
Known severe hypersensitivity reactions to monoclonal antibodies (grade >= 3 National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] version [v] 5.0), any history of anaphylaxis or history of uncontrolled asthma
Known severe hypersensitivity reactions to monoclonal antibodies (grade >= 3 National Cancer Institute [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] v4.03), any history of anaphylaxis, or recent (within 5 months) history of uncontrolled asthma.
Known severe hypersensitivity reactions to monoclonal antibodies (grade >= 3 National Cancer Institute [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] version [v]4.03)
Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (National Cancer Institute [NCI] CTCAE v5.0 grade >= 3)
Patients with a known allergy or hypersensitivity to the protocol therapies or any of their components to be used in the arm the patient is to be enrolled on. Known severe hypersensitivity reactions to monoclonal antibodies (grade >= 3 National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.03), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma).
Known severe (National Cancer Institute [NCI]- Common Terminology Criteria for Adverse Events [CTCAE] version [v]4.03 grade 3 or 4) infusion-related allergy or acute hypersensitivity reaction attributed to any monoclonal antibody, any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)
Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v]4.03 grade ? 3)
Known prior severe hypersensitivity to investigational product(s) or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v 4.03 grade >= 3).
Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v]4.03 grade ? 3)
Known severe hypersensitivity reactions to monoclonal antibodies (grade >= 3 National Cancer Institute [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.03), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)
Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI Common Terminology Criteria for Adverse Events [CTCAE] version [v]4.03 grade >= 3)
Known severe hypersensitivity reactions to monoclonal antibodies (grade >= 3 National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.03), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)
Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 grade >= 3)
Known severe hypersensitivity reactions to monoclonal antibodies (grade >= 3 National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.03), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)
Known severe hypersensitivity reactions to monoclonal antibodies or carboplatin >= grade 3, any history of anaphylaxis, or uncontrolled asthma
Known severe (grade >= 3 NCI-CTCAE version [v]4.03) hypersensitivity reactions to monoclonal antibodies, including hypersensitivity to the investigational agent or any component in its formulations, or history of anaphylaxis
Patients with a known allergy or hypersensitivity to avelumab, 5-azacytidine, or any of their components; known severe hypersensitivity reactions to monoclonal antibodies (grade >= 3 National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.03), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)
Known severe hypersensitivity reactions to monoclonal antibodies (grade >= 3 National Cancer Institute [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.0), any history of anaphylaxis, or uncontrolled asthma
Known severe hypersensitivity reactions to monoclonal antibodies (grade >= 3 National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] version [v]4.0), any history of anaphylaxis or uncontrolled asthma
Known severe hypersensitivity reactions to monoclonal antibodies, any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)
Known severe hypersensitivity reactions to monoclonal antibodies (Grade greater than or equal to (>=) 3 NCI CTCAE v 4.0), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)
History of severe hypersensitivity reaction to any monoclonal antibody (grade >= 3 National Cancer Institute [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] version [v] 4.03), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)
Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v]4.03 grade >= 3)
Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v]4.03 grade >= 3)
Known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE grade ?3), any history of anaphylaxis, or uncontrolled asthma (i.e., ?3 features of partly controlled asthma).
History of allergic reactions attributed to avelumab or any component in its formulations, or compounds of similar chemical or biologic composition to avelumab; known severe hypersensitivity reactions to monoclonal antibodies (grade >= 3 NCI CTCAE version [v] 4.03), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)
Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI Common Terminology Criteria for Adverse Events [CTCAE] version [v]4.03 grade >= 3)
Known severe (National Cancer Institute [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] version [v]4.03 grade 3 or 4) infusion-related allergy or acute hypersensitivity reaction attributed to any monoclonal antibody, any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)
History of severe allergic reactions to any unknown allergens or any components of the study drugs.
History of severe allergic reactions to vaccines or unknown allergens
Patients must not have a history of severe allergic reactions (i.e., grade 4 allergy, anaphylactic reaction from which the subject did not recover within 6 hours of institution of supportive care) to any unknown allergens or any components of the nivolumab formulations
Previous history of anaphylaxis or severe allergic reaction to hsp110, gp100, other vaccines, or unknown allergens
History of severe allergic reactions to any unknown allergens or any components of the study drugs.
History of severe allergic reactions to any unknown allergens or any components of the study drugs
History of severe allergic reactions to any unknown allergens or any components of the study drugs
History of severe allergic reactions to any unknown allergens or components of the study drugs.
History of severe allergic reactions to any unknown allergens or any components of the study drug formulations
History of severe allergic reactions to any unknown allergens or any components of the study drugs.
History of severe allergic reactions to vaccines or unknown allergens.
History of severe allergic reactions to any unknown allergens or any components of the study drug formulations.
No history of previous severe allergic reactions to vaccines or unknown allergens
Participants who have a known severe allergic response to one or more allergens, as defined by anaphylaxis.
Participants who have a known severe allergic response to one or more allergens, defined as anaphylaxis
Participants who have a known severe allergic response to one or more allergens
Patients with known potentially anaphylactic allergic reactions to gadolinium-diethylenetriamine penta-acetic acid (DTPA)
Patients with known potentially anaphylactic allergic reactions to gadolinium- diethylene triamine pentaacetic acid (DTPA)
Patients with a known allergy to gadolinium-DTPA
Known sensitivity to gadolinium-DTPA.
Known sensitivity to gadolinium-DTPA
Patients with known potentially anaphylactic allergic reactions to gadolinium-diethylenetriamine penta-acetic acid (DTPA)
Known allergic reaction to gadopentetate dimeglumine (Gd-DTPA)
Known allergic reaction to diethylene triamine pentaacetic acid (Gd-DTPA)
Known allergic reaction to gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA)
Known reaction to gadopentetate dimeglumine (Gd-DTPA)
Patients who have presence of a known contraindication to DCE-MRI may not participate in that portion of the study:\r\n* Known reaction to gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA), contrast agent \r\n* Chronic kidney disease\r\n* Nursing women
Women who have had a moderate or severe contrast reaction to intravenous gadolinium-diethylenetriamine pentaacetic acid (DTPA)
